Endometrioid Adenocarcinoma Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Endometrioid Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 115 of 15 trials

Recruiting
Phase 1

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Recurrent Endometrial CarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)60 enrolled14 locationsNCT05950464
Recruiting
Phase 3

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated Carcinoma+5 more
National Cancer Institute (NCI)360 enrolled408 locationsNCT05256225
Recruiting
Phase 2

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

Recurrent Endometrial CarcinomaEndometrial AdenocarcinomaEndometrial Clear Cell Adenocarcinoma+6 more
National Cancer Institute (NCI)81 enrolled136 locationsNCT05112601
Recruiting
Phase 2

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer

Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122
Recruiting
Phase 3

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

Stage IV Ovarian Cancer AJCC v8Stage IIIC Ovarian Cancer AJCC v8Advanced Ovarian Carcinoma+22 more
M.D. Anderson Cancer Center580 enrolled19 locationsNCT04575935
Recruiting

Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study

FIGO Grade 1 Endometrial Endometrioid AdenocarcinomaFIGO Grade 2 Endometrial Endometrioid AdenocarcinomaStage IA1 Endometrial Cancer FIGO 2023+1 more
Mayo Clinic212 enrolled20 locationsNCT06689956
Recruiting
Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Stage III Ovarian Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IIIA Ovarian Cancer AJCC v8+30 more
Ohio State University Comprehensive Cancer Center45 enrolled1 locationNCT05415709
Recruiting
Phase 1

ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

Endometrial CancerMetastasisEndometrial Endometrioid Adenocarcinoma+5 more
UNC Lineberger Comprehensive Cancer Center58 enrolled1 locationNCT05542407
Recruiting
Phase 3

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Ovarian CarcinomaOvarian High Grade Serous AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+6 more
NRG Oncology880 enrolled672 locationsNCT06580314
Recruiting
Phase 3

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

Endometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous Adenocarcinoma+6 more
University of Utah188 enrolled5 locationsNCT03422198
Recruiting

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Endometrial CancerEndometrioid AdenocarcinomaEndometrial Cancer Stage I
Memorial Sloan Kettering Cancer Center1,715 enrolled19 locationsNCT04291612
Recruiting

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

Endometrial CarcinomaEndometrial High Grade Endometrioid AdenocarcinomaStage II Endometrial Cancer+2 more
Mayo Clinic100 enrolled1 locationNCT07062016
Recruiting
Phase 2

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Advanced Ovarian CarcinomaAdvanced Fallopian Tube CarcinomaAdvanced Primary Peritoneal Carcinoma+15 more
Mayo Clinic78 enrolled3 locationsNCT06639074
Recruiting
Phase 1Phase 2

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798
Recruiting
Phase 2

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629